Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Inflammatory Bowel Disease II: Ulcerative Colitis

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Glucagon-like peptide-1 receptor agonists and pancreatic outcomes in chronic pancreatitis: a real-world cohort study.

BMC gastroenterology·2026

Same author

The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Pain Management in Chronic Pancreatitis: A Real-World Cohort Study.

Gastro hep advances·2026

Same author

Early Versus Delayed Pancreatic Enzyme Replacement Therapy After Pancreatic Cancer Surgery: A Real-World Cohort Study.

American journal of clinical oncology·2026

Same author

Small Bowel Cancer-Related Mortality in the United States, 1999 to 2024: A CDC WONDER Trend and Forecasting Analysis.

American journal of clinical oncology·2026

Same author

Persistently Elevated Gamma-Glutamyl Transferase and Hepatobiliary Malignancies: A Real-World Cohort Study.

Cancers·2026

Same author

Surgical versus conservative management of groove pancreatitis: a systematic review and meta-analysis.

Updates in surgery·2026

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Anti-inflammatory therapy in uveitis.

Parthopratim D Majumder¹, Sridharan Sudharshan, Jyotirmoy Biswas

¹Medical and Vision Research Foundations, Sankara Nethralaya, 18, College Road, Chennai - 600 006, India.

Recent Patents on Inflammation & Allergy Drug Discovery

|July 18, 2009

Summary

Researchers reviewed anti-inflammatory drugs and patents for treating intraocular inflammation, focusing on uveitis. This work systematizes knowledge on drug mechanisms and therapeutic benefits for improved patient outcomes.

More Related Videos

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Related Experiment Videos

Last Updated: Jun 21, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Area of Science:

Ophthalmology
Pharmacology
Immunology

Background:

Intraocular inflammation, particularly uveitis, requires effective management strategies.
Traditional treatments like antimetabolites and cytotoxic agents have limitations.
Emerging therapies, including biological drugs, show promise for anti-inflammatory action.

Purpose of the Study:

To conduct a bibliographic review of anti-inflammatory drugs for intraocular inflammation.
To compile recent patents related to these treatments.
To systematize current knowledge and elucidate drug mechanisms for uveitis.

Main Methods:

Bibliographic review of scientific literature.
Analysis of recent patent filings.
Compilation and synthesis of data on drug mechanisms and efficacy.

Main Results:

Diverse anti-inflammatory drugs and their mechanisms were identified.
Recent patents highlight advancements in drug development for uveitis.
Current knowledge on treatment modalities is being systematized.

Conclusions:

A comprehensive understanding of anti-inflammatory drugs is crucial for effective uveitis management.
Reviewing diverse drug classes and patents aids in advancing treatment options.
Elucidating drug mechanisms offers significant benefits for treating intraocular inflammation.